Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts give Contineum Therapeutics a consensus “Hold” rating: Of five analysts, three rate the stock a buy, one a hold, and one a sell. The average 12-month price target is $20.25.
• CTNM opened at $14.82, below the consensus target, with a 52-week range of $8.60 to $17.78 and a market capitalization of approximately $557.5 million.
• The company reported quarterly EPS of -$0.40, beating the consensus estimate of -$0.45; analysts expect a full-year EPS loss of $1.68.

Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) have been given a consensus rating of "Hold" by the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $20.25.

Several research analysts have recently weighed in on CTNM shares. Royal Bank Of Canada boosted their price objective on shares of Contineum Therapeutics from $22.00 to $23.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Contineum Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of Contineum Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, August 23rd.

Contineum Therapeutics Stock Performance

Shares of CTNM opened at $14.82 on Friday. The stock has a 50 day simple moving average of $15.38 and a 200 day simple moving average of $14.07. Contineum Therapeutics has a 52-week low of $8.60 and a 52-week high of $17.78. The firm has a market capitalization of $557.53 million, a PE ratio of -8.57 and a beta of 0.75.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.05. Equities research analysts predict that Contineum Therapeutics will post -1.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Contineum Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in shares of Contineum Therapeutics in the first quarter worth $27,000. Royal Bank of Canada increased its holdings in Contineum Therapeutics by 73.5% in the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company's stock valued at $76,000 after buying an additional 2,454 shares during the period. California State Teachers Retirement System bought a new position in Contineum Therapeutics in the 2nd quarter valued at about $99,000. Bank of America Corp DE raised its position in shares of Contineum Therapeutics by 500.0% in the 3rd quarter. Bank of America Corp DE now owns 7,236 shares of the company's stock valued at $85,000 after buying an additional 6,030 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Contineum Therapeutics in the 2nd quarter valued at approximately $43,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.